W. Forbes

A. Sanyal, E. Bortey, W. Forbes, 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

The Effect of Multiple‐Dose, Oral Rifaximin on the Pharmacokinetics of Intravenous and Oral Midazolam in Healthy Volunteers

W. Forbes, H. Pentikis, C. Trapnell, 2007, Pharmacotherapy.

A comparison of cilostazol and pentoxifylline for treating intermittent claudication.

D. Dawson, D. Strandness, D. Strandness, 2000, The American journal of medicine.

Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of Cilostazol

W. Forbes, S. Bramer, 1999, Clinical pharmacokinetics.

Pharmacokinetics of Multiple‐Dose Oral Cilostazol in Middle‐Age and Elderly Men and Women

W. Forbes, A. Suri, S. Bramer, 1998, Journal of clinical pharmacology.

Once-daily Mesalamine Formulation for Maintenance of Remission in Ulcerative Colitis: A Randomized, Placebo-controlled Clinical Trial

C. Paterson, E. Bortey, W. Forbes, 2015, Journal of clinical gastroenterology.

Clinical trial: once‐daily mesalamine granules for maintenance of remission of ulcerative colitis – a 6‐month placebo‐controlled trial

E. Bortey, W. Forbes, G. Lichtenstein, 2010, Alimentary pharmacology & therapeutics.

Safety and Efficacy of a New 3.3 g b.i.d. Tablet Formulation in Patients With Mild-to-Moderately-Active Ulcerative Colitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

W. Forbes, E. Scherl, Audrey L. Shaw, 2009, The American Journal of Gastroenterology.

Effect of Renal Impairment on the Pharmacokinetics of Cilostazol and its Metabolites

W. Forbes, S. Mallikaarjun, S. Bramer, 1999, Clinical pharmacokinetics.

Efficacy and Safety of Methylnaltrexone for Opioid-Induced Constipation in Patients With Chronic Noncancer Pain

E. Viscusi, C. Paterson, W. Forbes, 2015, Regional Anesthesia & Pain Medicine.

Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication

P. Thompson, W. Forbes, R. Zimet, 2002 .

Prevention of travelers' diarrhea with rifaximin in US travelers to Mexico.

H. Dupont, E. Bortey, W. Forbes, 2010, Journal of travel medicine.

Effect of Cilostazol on Treadmill Walking, Community‐Based Walking Ability, and Health‐Related Quality of Life in Patients with Intermittent Claudication Due to Peripheral Arterial Disease: Meta‐Analysis of Six Randomized Controlled Trials

J. Ware, J. Regensteiner, W. Hiatt, 2002, Journal of the American Geriatrics Society.

Polyp Detection Rate during Colonoscopy Is Correlated with Quality of Bowel Preparation: 1463

W. Forbes, L. Cohen, S. Lottes, 2006 .

Comment: Nifedipine in Hypertensive Emergencies

W. Forbes, D. Hilleman, D. Kohll, 1987, Drug intelligence & clinical pharmacy.

Rifaximin therapy for patients with irritable bowel syndrome without constipation.

W. Chey, A. Lembo, M. Pimentel, 2011, The New England journal of medicine.

Absence of Effect of Oral Rifaximin on the Pharmacokinetics of Ethinyl Estradiol/Norgestimate in Healthy Females

W. Forbes, H. Pentikis, C. Trapnell, 2007, The Annals of pharmacotherapy.

Prolonged remission from hepatic encephalopathy with rifaximin: results of a placebo crossover analysis

J. Bajaj, C. Paterson, E. Bortey, 2014, Alimentary pharmacology & therapeutics.

Development and Validation of a Biomarker for Diarrhea-Predominant Irritable Bowel Syndrome in Human Subjects

G. Barlow, A. Lembo, M. Pimentel, 2015, PloS one.

Effects of CYP3A Inhibition on the Metabolism of Cilostazol

W. Forbes, A. Suri, S. Bramer, 1999, Clinical pharmacokinetics.

Rifaximin treatment in hepatic encephalopathy.

C. Leevy, A. Sanyal, E. Bortey, 2010, The New England journal of medicine.

T1390 Rifaximin for the Treatment of Diarrhea-Associated Irritable Bowel Syndrome: Short Term Treatment Leading to Long Term Sustained Response

A. Lembo, M. Pimentel, Y. Ringel, 2008 .

Safety, Efficacy, and Pharmacokinetics of Balsalazide in Pediatric Patients With Mild-to-Moderate Active Ulcerative Colitis: Results of a Randomized, Double-blind Study

H. Pieniaszek, T. Attard, M. Heyman, 2009, Journal of pediatric gastroenterology and nutrition.

Once-Daily 1.5-G Granulated mesalamine Is Effective and Safe in Maintenance of Remission in Mild-to-Moderate Ulcerative Colitis: 1128

E. Bortey, W. Forbes, R. Pruitt, 2008 .

Once-Daily 1.5-G Granulated mesalamine Effectively Maintains Remission in Patients with Ulcerative Colitis Who Switch from Different 5-ASA Formulations: 1100

E. Bortey, W. Forbes, G. Lichtenstein, 2008 .

Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double‐blind, placebo‐controlled trials

W. Chey, L. Chang, P. Schoenfeld, 2014, Alimentary pharmacology & therapeutics.

T1152 Balsalazide Tablets 3.3g Twice Daily Improves Signs and Symptoms of Mild-to-Moderate Ulcerative Colitis

W. Forbes, B. Bosworth, M. Lamet, 2008 .

T1147 Twice-Daily Balsalazide Tablets Improve Patient Quality of Life After 2 and 8 Weeks of Treatment: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study

D. Rubin, W. Forbes, S. Sedghi, 2008 .

Tu1390 Improvement in Quality of Life of Patients With Irritable Bowel Syndrome With Diarrhea is Sustained for 10 Weeks Following a 2-Week Course of Rifaximin

A. Lembo, M. Pimentel, Lin Chang, 2012 .

Fixed-Dose Subcutaneous Methylnaltrexone in Patients with Advanced Illness and Opioid-Induced Constipation: Results of a Randomized, Placebo-Controlled Study and Open-Label Extension

J. Bull, C. Paterson, W. Forbes, 2015, Journal of palliative medicine.

A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial.

D. Dawson, D. Strandness, D. Strandness, 1999, Archives of internal medicine.

195 RIFAXIMIN DECREASES VENOUS AMMONIA CONCENTRATIONS AND TIME-WEIGHTED AVERAGE AMMONIA CONCENTRATIONS CORRELATE WITH OVERT HEPATIC ENCEPHALOPATHY (HE) AS ASSESSED BY CONN SCORE IN A 6-MONTH STUDY

A. Sanyal, E. Bortey, W. Forbes, 2010 .

15 RIFAXIMIN TREATMENT IMPROVED QUALITY OF LIFE IN PATIENTS WITH HEPATIC ENCEPHALOPATHY: RESULTS OF A LARGE, RANDOMIZED, PLACEBO-CONTROLLED TRIAL

A. Sanyal, E. Bortey, W. Forbes, 2010 .

109 LONG TERM EFFICACY AND SURVIVAL IN PATIENTS TREATED WITH THE GUT-SELECTIVE ANTIBIOTIC RIFAXIMIN (550 MG BID) FOR THE MAINTENANCE OF REMISSION FROM OVERT HEPATIC ENCEPHALOPATHY

J. Talwalkar, E. Bortey, W. Forbes, 2011 .

645 RATES OF COMMONLY OCCURING INFECTIONS IN CIRRHOSIS PATIENTS REMAIN STABLE DURING LONG-TERM RIFAXIMIN TREATMENT

A. Sanyal, E. Bortey, W. Forbes, 2012 .

Analysis of opioid-mediated analgesia in Phase III studies of methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain

L. Webster, C. Paterson, E. Bortey, 2015, Journal of pain research.

Patients Prefer New Sodium Phosphate (NaP) Tablets vs 2 L Polyethylene Glycol Electrolyte Lavage Solution (PEG) Plus Bisacodyl Tablets for Bowel Preparation: 1369

W. Forbes, G. Lichtenstein, S. Lottes, 2006 .

Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication.

J. Crouse, D. Hunninghake, M. Elam, 1998, Arteriosclerosis, thrombosis, and vascular biology.

Mesalazine granules 1.5 g once‐daily maintain remission in patients with ulcerative colitis who switch from other 5‐ASA formulations: a pooled analysis from two randomised controlled trials

E. Bortey, W. Forbes, G. Lichtenstein, 2012, Alimentary Pharmacology and Therapeutics.

Interaction Potential and Tolerability of the Coadministration of Cilostazol and Aspirin

W. Forbes, S. Mallikaarjun, S. Bramer, 1999, Clinical pharmacokinetics.

An interim analysis of a phase 2 trial evaluating oral nalbuphine extended release for treating chronic cough in idiopathic pulmonary fibrosis

T. Maher, E. Bortey, W. Forbes, 2022, 12.01 - Idiopathic interstitial pneumonias.

O-002 Evaluation of the Operating Properties of Candidate Patient Reported Outcomes for Use in Randomized Controlled Trials in Crohn’s Disease

M. Vandervoort, G. D'Haens, W. Sandborn, 2013 .

943a Oral Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Noncancer Pain

E. Bortey, W. Forbes, J. Peppin, 2012 .

Cilostazol Pharmacokinetics after Single and Multiple Oral Doses in Healthy Males and Patients with Intermittent Claudication Resulting from Peripheral Arterial Disease

W. Forbes, S. Mallikaarjun, S. Bramer, 1999, Clinical pharmacokinetics.

475i Rifaximin Treatment for 2 Weeks Provides Acute and Sustained Relief Over 12 Weeks of IBS Symptoms in Non-Constipated Irritable Bowel Syndrome: Results From 2 North American Phase 3 Trials (Target 1 and Target 2)

W. Chey, A. Lembo, M. Pimentel, 2010 .

Flecainide-induced cardiogenic shock.

D. Hillman, W. Forbes, S. Mohiuddin, 1988, Chest.

Rifaximin therapy for patients with irritable bowel syndrome without constipation.

W. Chey, A. Lembo, M. Pimentel, 2011, The New England journal of medicine.

Reporting of relapse rates in a trial of mesalazine for ulcerative colitis: authors’ reply

W. Forbes, G. Lichtenstein, 2010 .

Mo1116 The Efficacy and Safety of Rifaximin vs. Vancomycin in the Treatment of Mild to Moderate C. difficile Infection: A Randomized Double-Blind Active Comparator Trial

H. Dupont, D. Pardi, E. Bortey, 2012 .

A New Pharmacological Treatment for Intermittent Claudication

D. Dawson, E. Bortey, W. Forbes, 2017 .